MedTrace Logo

Efficacy of Targeted Abdominal Perfusion Pressure in Septic Shock

NCT05358912 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 85

Last updated 2022-11-29

No results posted yet for this study

Summary

Septic shock is a clinical condition that is defined as a subset of sepsis that causes very high mortality and morbidity.

Surviving sepsis campaign guideline states that the target mean arterial pressure should be 65 mmHg and above in septic shock patients. It is known that abdominal pressure increases and perfusion of intra-abdominal organs decreases in septic shock patients.

With this study, we aim to investigate the effects of targeted abdominal perfusion pressure (60 mmHg and above) on renal injury, reversal of renal injury, liver functions and ultimately mortality in patients with septic shock.

Conditions

  • Septic Shock
  • Septicemia
  • Intraabdominal Hypertension
  • Renal Injury

Interventions

DRUG

Vasopressor Agent

Patients will receive vasopressor agents according to "Surviving Sepsis Campaign Guidelines 2021"

DRUG

Crystalloid Solutions

Patients will receive crystalloid solutions according to "Surviving Sepsis Campaign Guidelines 2021"

PROCEDURE

Invasive Blood Pressure Monitoring

Invasive blood pressure monitoring will be performed through an intra-arterial cannula placed in the radial artery. Philips Intellivue mx 500 monitors will be used for bedside monitoring.

PROCEDURE

Intra-Abdominal Pressure Monitoring

IAP will be measured indirectly by monitoring the pressure in the bladder. Bladder pressure will be measured through an indwelling Foley catheter every twelve hours. Twenty-five mL of sterile normal saline will be injected in each measurement and readings will be recorded with a pressure transducer.

OTHER

Abdominal Perfusion Pressure

APP will be calculated with the following formula: (Mean arterial pressure) - (Intra-abdominal Pressure)

Sponsors & Collaborators

  • Bozyaka Training and Research Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-02
Primary Completion
2022-09-10
Completion
2022-09-21

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05358912 on ClinicalTrials.gov